Table 2.
Clinical trials using gold nanoparticles in photothermal therapy.
| Trial Number | Sponsor | Device | Disease | Number of enrolments | Number of centers | Status | Starting year | Ending year | Refs. |
|---|---|---|---|---|---|---|---|---|---|
| NCT01270139 | Ural State Medical University Ural Institute of Cardiology De Haar Research Task Force Ural Federal University Transfiguration Clinic |
Silica-GNP Silica-Iron-GNP |
Atherosclerosis | 60:60:60 | Multi- | Completed | 2007 | – | [35] [36] |
| CAS/OR/01/CMN/103300410C0010-1968/201 ∗ | Nanospectra Biosciences, Inc. | AuroShell | Prostate cancer | 22 | Multi- | Completed | – | – | [37] |
|
NCT02680535 (NBI-PC-002) |
Nanospectra Biosciences, Inc. | AuroShell | Prostate cancer | 16 | Multi- | Completed | 2016 | 2019 | [38] |
| – | Sebacia Inc. | Sebashell | Acne vulgaris | 37 | Multi- | Completed | – | – | [39] |
| YK/92/2016∗∗ | Nanfang University, China | GNRs @ Pd hydrogel eye patch | Dry eye syndrome | 20 | 1 | Completed | – | – | [40] |
| NCT02680535 | Nanospectra Biosciences, Inc. | AuroShell | Prostate cancer | 45 | Multi- | Completed | 2016 | 2019 | [41] |
| NCT04240639 | Nanospectra Biosciences, Inc. | AuroShell | Prostate cancer | 60 | Multi- | Recruiting | 2020 | 2023 | [42] |
| NCT01679470 | Nanospectra Biosciences, Inc. | AuroShell | Lung cancer | 1 | 1 | Terminated | 2012 | 2014 | [43] |
| NCT00848042 | Nanospectra Biosciences, Inc. | AuroShell | Head & neck cancer | 11 | 2 | Completed | 2008 | 2014 | [44] |
| NCT02219074 | Sebacia Inc. | Sebashell | Acne vulgaris | 350 | 2 | Completed | 2014 | 2016 | [45] |
∗ Research authorization number under the supervision of the Federal Commission for Protection against Health Risks (Comision Federal para la Proteccio n contra Riesgos Sanitarios, COFE-PRIS); ∗∗ Research Ethics Committee from Nanfang University, China. GNRs: Gold nanorods; Pd: Pallidium